Nuvectis Pharma reports Q3 results

3 hours ago 1

Nuvectis Pharma press release (NVCT): Q3 net loss was $7.5 million.
The increase in Q3 net loss was primarily due to a one-time $2.0 million milestone achievement expense for NXP900 and $0.7 million related to the clinical drug-drug interaction study, the company said.
Interest income was $0.3 million.
Cash runway expected to support the company’s operations into 3Q-2027.